Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BPTF | Q12830 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7421770 | 0.95 | NOS3 (0.45) | NOS3NOS1NOS2ACHEMAPK1 | |
| SCHEMBL22545792 | 0.93 | NOS3 (0.44) | NOS3NOS1NOS2ACHEMAPK1 | |
| SCHEMBL8057128 | 0.80 | HTR2C (0.35) | — | |
| SCHEMBL30932851 | 0.80 | HTR2C (0.35) | — | |
| Bromide SCHEMBL11076585 | 0.79 | HTR2C (0.34) | — | |
| SCHEMBL11076421 | 0.77 | HRH4 (0.42) | NOS1 | |
| Hydrochloric Acid SCHEMBL11074583 | 0.76 | HRH4 (0.41) | NOS1 | |
| SCHEMBL16418523 | 0.74 | PIK3R1 (0.31) | — | |
| SCHEMBL11064431 | 0.73 | HRH3 (0.41) | ACHERAB9A | |
| Hydrochloric Acid SCHEMBL11074582 | 0.73 | HRH3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| US-11220508-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11174265-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| US-20210230163-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-29 | — | — | US | disclosed |
| EP-3848370-A2 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-10793574-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190284194-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| US-10323036-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| WO-2018071794-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220508-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS1 4483/4885NOS2 4218/4885 |
| US-10793574-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS1 4483/4885NOS2 4218/4885 |
| US-10323036-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS1 4483/4885NOS2 4218/4885 |
| US-20210230163-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS1 4483/4885NOS2 4218/4885 |
| US-20190284194-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS1 4483/4885NOS2 4218/4885 |
| US-11174265-B2 | — | TYK2, JAK2, JAK1 | NOS3 3882/4885NOS1 4226/4885NOS2 3673/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS1 4483/4885NOS2 4218/4885 |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS1 4483/4885NOS2 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.